锚定“一体两翼”战略东北制药实现韧性成长

Core Viewpoint - Northeast Pharmaceutical is implementing a "one body, two wings" development strategy to enhance resilience and profitability amid industry challenges and competition [1][2] Group 1: Operational Efficiency - The company is improving operational quality and efficiency through a "production-sales collaboration, full-chain precision control" system, achieving a 100% product pass rate for the year [2] - Multiple products have received international certifications, enhancing market competitiveness [2] - The company is focusing on core products in the formulation sector, with sales of leading products reaching historical highs and market penetration increasing year-on-year [1][3] Group 2: Research and Innovation - Northeast Pharmaceutical is driving growth through both generic and innovative drugs, with three new generic drug products approved for market by 2025 [2][3] - The company is actively developing biopharmaceuticals and health products, including new health food and skincare items, to diversify its product matrix [2][3] - The company aims to revitalize five old product approvals within the year and accelerate the development of innovative drug projects [3] Group 3: Strategic Development - The "one body, two wings" strategy focuses on strengthening chemical generics while expanding into biomedicine and traditional Chinese medicine [2][4] - The company is enhancing its competitive edge by promoting health products, including cosmetics and food, which are currently in the early stages of market development [3] - A comprehensive support system is being established to ensure the effective implementation of the strategy, including optimizing management mechanisms and enhancing digital transformation [4]